Molecule Protocol

Molecule is a software platform to accelerate innovation in the pharmaceutical industry. It connects scientists, patients and industry to advance drug development in a collaborative open market.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

NEW AMR ACTION FUND STEPS IN TO SAVE COLLAPSING ANTIBIOTIC PIPELINE WITH PHARMACEUTICAL INDUSTRY INVESTMENT OF US$1 BILLION

AMR Action Fund | July 09, 2020

news image

Today, more than 20 leading biopharmaceutical companies announced the launch of the AMR Action Fund, a ground-breaking partnership that aims to bring 2-4 new antibiotics to patients by 2030. These treatments are urgently needed to address the rapid rise of antibiotic-resistant infections – also called antimicrobial resistance, or AMR. The companies have raised so far nearly US$1 billion new funding to support clinical research of innovative new antibiotics that are addressing the most resi...

Read More

BUSINESS INSIGHTS

TELIX GRANTED FDA ORPHAN DRUG DESIGNATION FOR BONE MARROW CONDITIONING TREATMENT

Telix Pharmaceuticals Limited | March 29, 2022

news image

Telix Pharmaceuticals Limited announces that the United States Food and Drug Administration has granted Orphan Drug Designation for TLX66 for conditioning treatment prior to hematopoietic stem cell transplant. The granting of an ODD for TLX66 qualifies Telix for various drug development incentives, which may include FDA administered market exclusivity for seven years, waived FDA prescription drug user fees, and tax credits for R&D and clinical development costs. Bone marrow co...

Read More

MODERNA TAKES $1.5B CONTRACT WITH U.S. GOVT. FOR COVID-19 VACCINE

Moderna | August 13, 2020

news image

Through its COVID-19 vaccine partnership with the U.S. government, Moderna picked up nearly $1 billion in research aid. Now, it's joining a list of other companies to take a supply order from the federal government. Under a deal worth up to $1.525 billion, Moderna agreed to deliver 100 million doses of its mRNA vaccine candidate if it succeeds in late-stage testing. The deal doesn’t stipulate a timeline for vaccine shipments, at least publicly, but does include “incentive payment...

Read More

BUSINESS INSIGHTS

ERT EXPANDS CLINICAL IMAGING REPORTING CAPABILITIES IN ITS BUSINESS INTELLIGENCE SUITE

ERT | April 16, 2021

news image

ERT, the worldwide pioneer in clinical endpoint data collection, today declared that its demonstrated Business Intelligence suite has extended to incorporate detailing for clinical preliminary imaging, making study data all the more effectively available and noteworthy. The new imaging capabilities give an elevated degree of data that empowers study pioneers to guarantee consummation, and successfully oversee locales, expenses, and profitability. "Imaging studies are complex,...

Read More
news image

NEW AMR ACTION FUND STEPS IN TO SAVE COLLAPSING ANTIBIOTIC PIPELINE WITH PHARMACEUTICAL INDUSTRY INVESTMENT OF US$1 BILLION

AMR Action Fund | July 09, 2020

Today, more than 20 leading biopharmaceutical companies announced the launch of the AMR Action Fund, a ground-breaking partnership that aims to bring 2-4 new antibiotics to patients by 2030. These treatments are urgently needed to address the rapid rise of antibiotic-resistant infections – also called antimicrobial resistance, or AMR. The companies have raised so far nearly US$1 billion new funding to support clinical research of innovative new antibiotics that are addressing the most resi...

Read More
news image

BUSINESS INSIGHTS

TELIX GRANTED FDA ORPHAN DRUG DESIGNATION FOR BONE MARROW CONDITIONING TREATMENT

Telix Pharmaceuticals Limited | March 29, 2022

Telix Pharmaceuticals Limited announces that the United States Food and Drug Administration has granted Orphan Drug Designation for TLX66 for conditioning treatment prior to hematopoietic stem cell transplant. The granting of an ODD for TLX66 qualifies Telix for various drug development incentives, which may include FDA administered market exclusivity for seven years, waived FDA prescription drug user fees, and tax credits for R&D and clinical development costs. Bone marrow co...

Read More
news image

MODERNA TAKES $1.5B CONTRACT WITH U.S. GOVT. FOR COVID-19 VACCINE

Moderna | August 13, 2020

Through its COVID-19 vaccine partnership with the U.S. government, Moderna picked up nearly $1 billion in research aid. Now, it's joining a list of other companies to take a supply order from the federal government. Under a deal worth up to $1.525 billion, Moderna agreed to deliver 100 million doses of its mRNA vaccine candidate if it succeeds in late-stage testing. The deal doesn’t stipulate a timeline for vaccine shipments, at least publicly, but does include “incentive payment...

Read More
news image

BUSINESS INSIGHTS

ERT EXPANDS CLINICAL IMAGING REPORTING CAPABILITIES IN ITS BUSINESS INTELLIGENCE SUITE

ERT | April 16, 2021

ERT, the worldwide pioneer in clinical endpoint data collection, today declared that its demonstrated Business Intelligence suite has extended to incorporate detailing for clinical preliminary imaging, making study data all the more effectively available and noteworthy. The new imaging capabilities give an elevated degree of data that empowers study pioneers to guarantee consummation, and successfully oversee locales, expenses, and profitability. "Imaging studies are complex,...

Read More